Update on Progress of LAGEVRIO™ (molnupiravir) Supply and Access Strategy

As of March 31, 2022, we have committed to providing approximately 10 million courses of LAGEVRIO™ (molnupiravir) through nearly 40 supply and purchase agreements. In the first quarter, Merck delivered 4.9 million courses of LAGEVRIO globally, resulting in a total of 6.4 million courses delivered to more than 30 countries to date. These figures exclude potential deliveries associated with Merck's agreement with UNICEF, as detailed below.

Our efforts to accelerate access to LAGEVRIO equitably and affordably upon authorization or approval in low- and middle-income markets began early through the granting of non-exclusive voluntary licenses to multiple generic manufacturers (April 2021) and by entering into an agreement with Medicines Patent Pool through which 27 sub-licenses have been granted to generic manufacturers (October 2021). Through these voluntary licenses, generic manufacturers have sold more than 2.5 million courses of molnupiravir to approximately 15 markets through March 2022. Merck also entered into a supply agreement with UNICEF (January 2022) for Merck to provide up to 3 million courses of Merck-produced LAGEVRIO for use in low- and middle-income countries.

LAGEVRIO is currently available in more than 30 markets, including in the U.K. (under Conditional Marketing Authorization), the U.S. (under Emergency Use Authorization), and Japan (under Special Approval for Emergency), with plans to seek authorization or approval in additional markets around the world. LAGEVRIO is being developed by Merck in collaboration with Ridgeback Biotherapeutics.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA.

This statement of Merck & Co., Inc., Kenilworth, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other

protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2021, and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

###